Study of adverse reactions following subcutaneous allergen-specific immunotherapy in children with allergic rhinitis

The steady increase in the incidence of allergic diseases among the population testifies to insufficient control of allergic diseases. The method of subcutaneous allergen-specific immunotherapy (SCIT) remains frequently used among children due to its proven high efficacy and long-term clinical effect. High commitment to the completion of the protocol and high awareness of the parents about possible adverse reactions determines the effectiveness of SCIT. The article is aimed at evaluation of the safety of SCIT in children with allergic rhinitis. The study included children from 7 to 17 years old with Ig-E mediated allergic rhinitis. We have assessed the frequency of local and systemic adverse reactions. During the period from October 2020 to December 2023, 130 patients underwent SCIT at VITA-Med Medical Center (Ulan-Ude). Their average age is 12±3.2 years, 62 (47.69%) are boys and 68 (52.30%) are girls. There were no systemic adverse reactions. Local skin adverse reactions in the form of local hyperemia and edema developed in 54 (41.54%) children. It has been noted that allergen concentrations in dilution 10-3, 10-2 are the most reactogenic. Symptomatic therapy was needed only in 5 cases. The study confirmed the good tolerability and high safety profile of SCIT in real clinical practice in children with allergic rhinitis.